This study was conducted to determine the seroprevalence of HCV and HIV antibodies in TB confirmed patient attending the Federal Medical Centre (FMC), Ido Ekiti, Ekiti State, Nigeria. A total of 500 tuberculosis confirmed patients were selected by random sampling. Their blood samples were collected and assayed for HCV and HIV antibodies using Clinotech diagnostic Anti-HCV detection test and Abbot determine HIV ½  in conjunction with Chembio HIV ½ STAT-PAK assay kit respectively. Out of 500 TB patients tested, 10(2.0%), 21(4.2%) and 3(0.6%) tested positive to HCV, HIV, and HCV/HIV antibodies respectively. Age group 36-45 was the most prevalence of HCV, HIV, and HCV/HIV antibodies with P-value 0.000, 0.000 and 0.002 respectively. The associated risk factors were alcoholism 14 (45.2%), being the highest identified risk factor, followed by previous unprotected sex, multiple sex partner, previous blood donor, previous transfusion, tattoos, and history of the Sexually transmitted disease being the least risk factor 3 (9.68%). The degree of disparity in regards to HCV, HIV and co-exists of HCV/HIV antibodies between 302 male and 198 female that participated were not statistically significant. (P-value 0.531, 0.549,and 0.824 for HCV, HIV and HCV/HIV antibodies respectively).These findings confirmed that both HCV and HIV can co-exist in TB patients, and may increase the risk of antituberculosis drug-induced hepatotoxicity, if overlooked, there will be a greater risk for TB patients, and these infections will continue to spread through the associated risk factors. However, in managing the TB patients, there is a need to screen for Anti- HCV, as it has been for HIV antibody.

Rubella virus infection poses a great threat to the foetus whose mother acquires the infection. This study was therefore carried out to determine the seroprevalence of rubella virus IgM antibodies among the pregnant women attending Federal Teaching Hopsital, Ido Ekiti. One hundred and ninety two (192) sera were collected from pregnant women and screened for rubella virus IgM antibodies. A structured questionnaire was administered to subjects to obtain socio-demographic data. The sera samples were analysed using Enzymes Immunosorbent Assay (EIA) IgM rubella kit. Out of 192 pregnant women screened, 6(3.1%) subjects were sero-positive. Age group 31-35years recorded the highest prevalence 3(1.56%). Pregnant women with tertiary education had the highest prevalence of 4(2.08%) among different educational level; civil servants have a prevalence of 4(2.08%) compared with other occupational status. However, prenatal screening and post-partum is highly encouraged to detect congenital rubella syndrome. There is also a need to include rubella screening as part of the routine procedure for the expectant mother.